| 庄灿,陈敏,刘桠,高泓,谢春光.参芪复方对GK大鼠主动脉血管紧张素Ⅱ1型受体mRNA表达的影响[J].,2013,33(3):351-355 |
| 参芪复方对GK大鼠主动脉血管紧张素Ⅱ1型受体mRNA表达的影响 |
| Effects of Shenqi Compound on the mRNA Expression of AT1R in the Aorta of GK Rats |
| |
| DOI： |
| 中文关键词: 参芪复方 糖尿病大血管病变 血管紧张素Ⅱ 血管紧张素Ⅱ1型受体 |
| 英文关键词:Shenqi Compound diabetic macrovascular disease angiotensin Ⅱ angiotensin Ⅱ type 1 receptor |
| 基金项目:国家自然科学基金资助项目（No.30772806） |
|
| Hits: 1749 |
| Download times: 917 |
| 中文摘要: |
| 目的 观察参芪复方对GK（Goto-Kakizaki）大鼠大血管病变主动脉血管紧张素Ⅱ1型受体（angiotensin Ⅱ type 1 receptor，AT1R） mRNA表达的影响。方法 67只GK大鼠随机分为GK组（18只）、模型组（16只）、阿托伐他汀组（17只）及参芪复方组（16只），另设正常Wistar对照组（18只）。以L-NAME 0.10 mg/（mL·d）加入大鼠饮用水中复制糖尿病大血管病变模型。除正常Wistar对照组外，其他4组均喂饲高脂饲料。阿托伐他汀组及参芪复方组分别按1.60 mg/（kg·d）、1.44 g/（kg·d）灌胃相应药物，均每天1次，连续35天。采用葡萄糖氧化酶法每周测定血糖1次；给药5周后，夹心酶联免疫吸附法测定甘油三酯（TG）及总胆固醇（TC）水平，放射免疫法检测血清血管紧张素Ⅱ（angiotensin Ⅱ，AngⅡ）水平，实时定量聚合酶链反应（RT-PCR）检测主动脉AT1R mRNA表达。结果 给药4周末阿托伐他汀组和参芪复方组血糖水平均较本组给药前明显降低（P<0.05），且参芪复方组明显低于模型组同期（P<0.05）。模型组TC、TG、血清AngⅡ及主动脉AT1R mRNA水平均明显高于正常Wistar对照组（P<0.01）。给药5周后，阿托伐他汀组和参芪复方组TC、TG、AngⅡ及AT1R mRNA水平明显低于模型组（P<0.01，P<0.05）。阿托伐他汀组AT1R mRNA明显低于参芪复方组（P<0.05）。结论 参芪复方可降低GK大鼠早期大血管病变模型的血糖、血脂，减少血清AngⅡ含量及主动脉AT1R mRNA表达。AT1R可能是参芪复方治疗糖尿病大血管病变的有效靶点之一。 |
| 英文摘要: |
| Objective To observe the effects of Shenqi Compound （SQC） on the mRNA expression of angiotensin Ⅱ type 1 receptor （AT1R） in the aorta of Goto-Kakizaki （GK） rats. Methods Totally 67 GK rats were randomly divided into 5 groups， i.e.， the GK group （n=18）， the model group （n=16）， the atorvastatin group （n=17）， and the SQC group （n=16）. Another a normal control group was set up （n=18）. The diabetic macrovascular disease model was prepared by adding L-NAME （at the daily dose of 0.10 mg/mL） in drinking water for GK rats. GK rats， except those in the normal control group were fed with high fat diet. Atorvastatin （at the daily dose of 1.60 mg/kg） and SQC （at the daily dose of 1.44 g/kg） were respectively administered by gastrogavage， once daily for 35 successive days. The blood glucose was determined by glucose oxidase method once per week. After 5-week medication， the contents of triglyceride （TG） and total cholesterol （TC） were determined by ELISA. The serum concentrations of angiotensin Ⅱ （AngⅡ ） were determined by RIA. The mRNA expression of AT1R in the aorta was determined by real-time quantitative reverse transcriptase PCR （RT-PCR）. Results The blood glucose level was obviously lower in both the atorvastatin group and the SQC group after 4 weeks of medication （P<0.05）. Besides， it was significantly lower in the SQC group than in the model group by the end of the 4th week （P<0.05）. The concentrations of TG， TC and serum AngⅡ ， and the mRNA expression of AT1R in the aorta were significantly higher in the model group than in the normal control group （P<0.01）. After 5-week medication， the concentrations of TG， TC and serum AngⅡ ， and the mRNA expression of AT1R in the aorta were significantly lower in the atorvastatin group and the SQC group than in the model group （P<0.01， P<0.05）. The mRNA expression of AT1R was significantly higher in the SQC group than in the atorvastatin group （P<0.05）. Conclus ionsSQC could significantly reduce the levels of blood glucose， TG， TC， down-regulate the mRNA expression of AT1R in the aorta， and decrease the expressions of serum Ang Ⅱ of GK rats with diabetic macrovascular disease. AT1R might be one of effective targets of SQC in treating diabetic macrovascular diseases. |
| View Full Text View/Add Comment Download reader |
